Edesa Biotech, Inc. (EDSA) Stock Analysis & Investment Frameworks
Edesa Biotech, Inc. (EDSA) stock analysis on Invetso. Review Edesa Biotech, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Edesa Biotech, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: CA
Edesa Biotech, Inc. Key Financial Metrics
- Market Cap: $20.52M
- Revenue: $N/A
- ROE: -124.21%
- ROIC: -166.02%
- Dividend Yield: N/A
About Edesa Biotech, Inc.
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Edesa Biotech, Inc. Investment Frameworks
Invetso analyzes Edesa Biotech, Inc. (EDSA) across the following frameworks:
- Edesa Biotech, Inc. 10Y Growth Potential
- Edesa Biotech, Inc. Scenario Analysis
- Edesa Biotech, Inc. Risks & Opportunities
- Edesa Biotech, Inc. Economic Moat
- Edesa Biotech, Inc. Business Model
- Edesa Biotech, Inc. Management
- Edesa Biotech, Inc. SWOT Analysis
- Edesa Biotech, Inc. Porter's 5 Forces
- Edesa Biotech, Inc. PESTLE Analysis
- Edesa Biotech, Inc. ESG Analysis